March 2009
Worldwide Biotech;Mar2009, Vol. 21 Issue 3, p5
Trade Publication
This article reports on the results from MINDSET-01, an exploratory phase II clinical trial evaluating dirucotide in patients with relapsing-remitting multiple sclerosis (MS), released by BioMS Medical Corp. The results of the study showed that dirucotide did not meet its primary endpoint, annualized relapse rate or associated secondary magnetic resonance imaging (MRI) endpoints. The study also revealed that the drug did meet certain secondary endpoints related to the progression of the disease.


Related Articles

  • Overview of London trial of intramuscular interferon-β1a in primary-progressive multiple sclerosis. Miller, David H.; Leary, Siobhan M.; Thompson, Alan J. // Multiple Sclerosis (13524585);Jun2004 Supplement, Vol. 10, p56 

    This short monograph describes the rationale, design and outcome of a pilot study of beta interferon in patients with primary progressive MS. A total of 50 patients were studied for 2 years using a randomized, double-blinded, placebo-controlled design. There was an emphasis on using MRI measures...

  • Glatiramer effective in delaying clinical MS.  // Formulary;Jun2008, Vol. 43 Issue 6, p220 

    The article reports on the findings of the study called PRECISE, a randomized trial of patients presented with a single clinical episode and a magnetic resonance imaging (MRI) scan suggestive of multiple sclerosis (MS). This study found that glatiramer provides a new option for delaying...

  • Methodology of clinical trials in multiple sclerosis. Mitsikostas, D. D. // Neurological Sciences;Sep2006 Supplement 5, Vol. 27, ps362 

    The scope of the paper is to summarise key issues in methodology used in clinical trials on multiple sclerosis (MS) treatment and help clinicians to better understand articles reporting the results of these trials. Relapsing ratio and disability progression based on the Expanded Disability...

  • In the news and on our Web site.  // Momentum (19403410);Spring2008, Vol. 1 Issue 2, p74 

    This section offers news briefs on issues related to multiple sclerosis (MS) research. A large-scale analysis suggested that disease-modifying drugs for MS are effective in delaying disability progression in people whose MS started with relapses. Enrollment has begun for two large-scale clinical...

  • Multiple Sclerosis Update.  // PharmaWatch: CNS;Apr2008, Vol. 7 Issue 4, p7 

    The article offers news briefs related to results of clinical trials for treatment of multiple sclerosis. BioMS Medical Corp. has revealed that the Data Safety Monitoring Board (DSMB) has recommended to the company to continue the trial for its MBP8298 drug. Likewise, Opexa Therapeutics Inc. has...

  • Does MRI lesion activity regress in secondary progressive multiple sclerosis? Zhao, Y.; Petkau, A. J.; Traboulsee, A.; Riddehough, A.; Li, D. K. B. // Multiple Sclerosis (13524585);Apr2010, Vol. 16 Issue 4, p434 

    Background: The rate of new contrast-enhancing lesions (CELs) on monthly magnetic resonance imaging (MRI) scans has been shown to decrease over a 9-month period in placebo-treated patients with relapsing-remitting (RR) multiple sclerosis (RRMS). Objective: We examined this phenomenon in...

  • Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis. Comi, Giancarlo; Filippi, Massimo; Rocca, Maria A.; Jeffery, Douglas; Kappos, Ludwig; Montalban, Xavier; Boyko, Alexey // New England Journal of Medicine;3/15/2012, Vol. 366 Issue 11, p1000 

    Background: Two proof-of-concept clinical trials have provided evidence that laquinimod reduces disease activity in patients with relapsing�remitting multiple sclerosis. Methods: We conducted a randomized, double-blind, phase 3 study at 139 sites in 24 countries. A total of 1106 patients...

  • Controversies in Multiple Sclerosis Therapy. Rizzo, Toni // MD Conference Express;Jun2014, Vol. 14 Issue 6, p18 

    Considerable progress has been made in multiple sclerosis (MS) therapy in the 20 years since the first successful trial. Although several agents are now available for treating patients with MS, many issues remain regarding treatment of individual patients. This article discusses initiating MS...

  • Magnetic resonance imaging as surrogate for clinical endpoints in multiple sclerosis: data on novel oral drugs. Sormani, M. P.; Bonzano, L.; Roccatagliata, L.; De Stefano, N. // Multiple Sclerosis Journal;May2011, Vol. 17 Issue 5, p630 

    Recent studies have provided evidence for using magnetic resonance imaging (MRI) active lesions as surrogate for relapses and disability progression in multiple sclerosis (MS). However, the validity of MRI metrics as surrogate endpoints in MS is controversial. Furthermore, the extrapolation of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics